Physician profile
Suzanne H Shaffer
NPI 1528056157
$5,621.86
in general payments reported to CMS, 2019-2025
37 companies · $574 in 2025
The $574 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $755 · 2021: $1,083 · 2022: $727 · 2023: $909 · 2024: $767 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,108.08 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $700.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $627.07 | 2019-2022 | |
| Amgen INC. | $466.32 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $441.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $249.69 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.07 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $225.79 | 2019-2025 | Zoryve, Livalo |
| Pfizer INC. | $208.51 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $164.71 | 2021-2023 | Ajovy |
| Idorsia Pharmaceuticals US INC | $143.45 | 2023 | Quviviq |
| Antares Pharma, INC. | $136.89 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $68.93 | 2021 | |
| Abbott Laboratories | $62.96 | 2022-2023 | Freestyle Libre 2 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.00 | 2019-2024 | Proquad, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $56.47 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $56.46 | 2021-2023 | Shingrix, Arexvy |
| Genentech USA, INC. | $51.58 | 2019-2021 | |
| Ibsa Pharma INC. | $48.40 | 2021-2025 | Tirosint, Licart, Tirosint |
| Neos Therapeutics, LP | $47.00 | 2020-2022 | |
| Boston Scientific Corporation | $41.42 | 2024 | Watchman Flx |
| Astellas Pharma US INC | $36.76 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $34.55 | 2019-2023 | Thinprep 2000 Processor, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $33.83 | 2021-2022 | |
| Adlon Therapeutics L.P. | $29.50 | 2020 | |
| Cequr Corporation | $26.09 | 2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $26.00 | 2024 | |
| Shire North American Group INC | $24.41 | 2019 | |
| Allergan, INC. | $19.10 | 2020 | |
| Agile Therapeutics, INC. | $18.24 | 2024 | Twirla |
| Dexcom, INC. | $17.25 | 2025 | Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $16.10 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.46 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.03 | 2024 | Unithroid |
| Clarus Therapeutics INC. | $13.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.